Teacher Retirement System of Texas Boosts Position in Insulet Co. (NASDAQ:PODD)

Teacher Retirement System of Texas raised its stake in shares of Insulet Co. (NASDAQ:PODD) by 1.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,328 shares of the medical instruments supplier’s stock after buying an additional 187 shares during the quarter. Teacher Retirement System of Texas’ holdings in Insulet were worth $4,785,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. SBI Securities Co. Ltd. purchased a new position in Insulet during the 4th quarter valued at about $36,000. SRS Capital Advisors Inc. grew its holdings in Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after buying an additional 56 shares in the last quarter. TD Private Client Wealth LLC grew its holdings in Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 56 shares in the last quarter. Friedenthal Financial purchased a new position in Insulet during the 4th quarter valued at about $57,000. Finally, Assetmark Inc. grew its holdings in Insulet by 1,447.1% during the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock valued at $69,000 after buying an additional 246 shares in the last quarter.

Insulet Stock Performance

NASDAQ:PODD opened at $268.32 on Monday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The business has a 50 day moving average of $272.04 and a 200 day moving average of $257.37. The company has a market capitalization of $18.84 billion, a price-to-earnings ratio of 46.34, a PEG ratio of 3.62 and a beta of 1.29. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The business had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. On average, sell-side analysts predict that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on PODD shares. Royal Bank of Canada assumed coverage on Insulet in a report on Thursday, March 6th. They set an “outperform” rating and a $340.00 target price for the company. Wells Fargo & Company lifted their price target on Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Raymond James reiterated an “outperform” rating and set a $328.00 price target (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. StockNews.com downgraded Insulet from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. lifted their price target on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research report on Thursday, December 12th. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $292.06.

Insiders Place Their Bets

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.47% of the company’s stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.